Pine Labs' shares experienced a significant increase of up to 4.5%, reaching a high of Rs 152.80 on the Bombay Stock Exchange (BSE) following the announcement of its Q4 results. The company reported a consolidated net profit of Rs 59 crore for the quarter ended March 2026, a notable recovery from a net loss of Rs 29 crore during the same period last year. Revenue from operations for Q4FY26 rose 17% year-on-year to Rs 701 crore. For the entire financial year FY26, Pine Labs achieved a revenue of Rs 2,711 crore, marking a 19% increase from FY25. Morgan Stanley has set a target price of Rs 245 for Pine Labs, implying a 67% upside, despite some revenue growth falling slightly below consensus estimates. The brokerage noted strong growth in the company’s issuing and acquiring business, alongside improvements in operating leverage and cash flow conversion. However, it also acknowledged challenges due to geopolitical tensions affecting the international business. Pine Labs shares have declined 24% in the last month and 36% since the start of the year, following its IPO debut at Rs 242 per share in November 2023.